MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results por Sallman, D, Malki, MA, Asch, A, Wang, E, Jurcic, J, Bradley, T, Flinn, I, Pollyea, D, Kambhampati, S, Tanaka, T, Zeidner, J, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N